Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Leerink Partners Upgrades Gilead Sciences (GILD)
Fintel reports that on October 21, 2024, Leerink Partners upgraded their outlook for Gilead Sciences (NasdaqGS:GILD) from Market Perform to Outperform. Analyst Price Forecast Suggests 3.16% Downside As of September 24,
Gilead upgraded to outperform by Leerink on PreEP outlook
Leerink has upgraded Gilead Sciences (NASDAQ:GILD) to outperform, citing the growth outlook for its PrEP treatment lenacapavir for the prevention of HIV infection. The investment firm said that “any success” with data readouts for Gilead's (GILD) longer-acting HIV drugs “has an outsize impact on GILD’s” valuation,
Gilead upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $96, up from $74. The stock has appreciated following
2d
on MSN
Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High Consensus ROE
We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The Highest Consensus ROE. In this ...
11h
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new results from a Phase 2 clinical ...
12h
Solid Investment Potential: Buy Rating for Gilead Sciences Amid Positive Revenue Adjustments and Growth Commitment
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...
Benzinga.com
4d
Here's How Much $100 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Gilead Sciences
GILD
has outperformed the market over the past 20 years by 3.74% on an annualized basis producing an ...
stocknews
6d
3 Biotech Stocks Set to Revolutionize Medicine
The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To ...
Seeking Alpha
3d
GILD Gilead Sciences, Inc.
View Gilead Sciences, Inc. (
GILD
) current and estimated P/E ratio data provided by Seeking Alpha.
Fox Business
4d
gilead sciences inc. - GILD
Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the health care sector on Friday, sending the drugmaker's stock price soaring while ...
8h
Gilead, MRK Report Data From Investigational Combination Study for HIV
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
NASDAQ
Leerink
HIV
Trodelvy
lenacapavir
Feedback